Anti-TNF-Alpha Therapy and Systemic Vasculitis
Joint Authors
Kaplanski, Gilles
Jarrot, Pierre-André
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-02-27
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
TNF-α is a pleiotropic cytokine, which plays a major role in the pathogenesis of numerous autoimmune and/or inflammatory systemic diseases.
Systemic vasculitis constitutes a group of rare diseases, characterized by inflammation of the arterial or venous vessel wall, causing stenosis and thrombosis.
Treatment of the different type of vasculitis mainly relies on steroids and immunosuppressive drugs.
In case of refractory or relapsing diseases, however, a second line of treatment may be required.
Anti-TNF-α drugs have been used in this setting during the last 15 years with inconsistent results.
We reviewed herein the use of anti-TNF-α therapy in different kind of vasculitis and concluded that, except for Behcet’s disease, this therapeutic option has not demonstrated significant improvement in the treatment of vasculitis.
American Psychological Association (APA)
Jarrot, Pierre-André& Kaplanski, Gilles. 2014. Anti-TNF-Alpha Therapy and Systemic Vasculitis. Mediators of Inflammation،Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-1043604
Modern Language Association (MLA)
Jarrot, Pierre-André& Kaplanski, Gilles. Anti-TNF-Alpha Therapy and Systemic Vasculitis. Mediators of Inflammation No. 2014 (2014), pp.1-9.
https://search.emarefa.net/detail/BIM-1043604
American Medical Association (AMA)
Jarrot, Pierre-André& Kaplanski, Gilles. Anti-TNF-Alpha Therapy and Systemic Vasculitis. Mediators of Inflammation. 2014. Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-1043604
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1043604